AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00185796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin as Conditioning (ATG)
Description: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
Study NCT02565888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Study NCT02565888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02565888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Study NCT02565888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Study NCT02565888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Study NCT02565888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Study NCT03561025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-FDG
Study NCT03561025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-FDG
Study NCT03561025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GE180-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-GE180
Study NCT00006220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Study NCT03216603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy intervention group
Description: In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
Study NCT03561025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-GE180-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-GE180
Study NCT02956278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study NCT02956278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Study NCT02956278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose placebo pill
Study NCT02956278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose placebo pill
Study NCT02782208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox
Description: Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
Study NCT02782208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered 4 times previous to and during the investigation day.
Study NCT02782208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GH substitution
Description: GH substitution as usually
Study NCT02782208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GH substitution
Description: GH substitution as usually
Study NCT03080480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily.
Study NCT03743480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early palliative care
Description: experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
Study NCT03760458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Description: Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
Study NCT03760458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Description: Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
Study NCT02782208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GH pause
Description: GH substitution pause two days prior to the experimental day
Study NCT02782208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GH pause
Description: GH substitution pause two days prior to the experimental day
Study NCT01072981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Pancreas Immunotherapy
Description: Up to 18 immunizations of 300 million immunotherapy cells
Study NCT01072981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2/day once a week for 3 weeks
Study NCT01072981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2/day once a week for 3 weeks
Study NCT01072981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5FU Chemoradiation
Description: 5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
Study NCT01072981 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5FU Chemoradiation
Description: 5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
Study NCT03777111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
Study NCT03777111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
Study NCT01249833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75mg BID for 5 days
Study NCT02203162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic cigarette exposure
Description: 30 puffs of a disposable electronic cigarette, 30 seconds apart.
Study NCT00989898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated closed-loop insulin delivery
Description: Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
Study NCT03834155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based CR + Movn Application
Description: Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
Study NCT03834155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of Hospital or home-based CR + Movn Application
Description: Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
Study NCT03834155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based CR + Movn Application + Nudge
Description: Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
Study NCT03834155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of Hospital or home-based CR + Movn Application + Nudge
Description: Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
Study NCT00092521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
Study NCT00092521 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
Study NCT00092521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus (HPV) 16 Monovalent
Description: HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
Study NCT02239081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730
Study NCT02239081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730
Study NCT02702141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD19B
Description: Given intravenously Day 1 of 28-day or 42-day cycles
Study NCT04892992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DFG
Study NCT01065064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RESTOR IOL
Description: The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
Study NCT02107950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa in parallel with chemotherapy
Description: DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
Study NCT02107950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
Study NCT01403506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl Cysteine
Description: 600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
Study NCT03875976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track Protocol
Description: Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
Study NCT03875976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Protocol
Description: Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
Study NCT02414802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a manual spiral thrombus broken suction device
Description: A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
Study NCT02414802 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis will be used in both arms
Study NCT01417702 — intervention group
Intervention type: DEVICE
Intervention: High-definition white light endoscopy and i-Scan
Description: Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
Study NCT01064882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution 0.005%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
Study NCT01064882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution 0.015%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
Study NCT01064882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
Study NCT03258502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 drug in capsules
Study NCT03258502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in capsules
Study NCT04786483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Theraphy
Description: Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed.
Study NCT03015870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal exercise with real-time feedback
Description: The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
Study NCT03015870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal exercise with recording
Description: The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
Study NCT06289023 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HA-WBRT-SIB
Description: A total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV were boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week.
Study NCT01016223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
Study NCT01016223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo swallowed two puffs twice daily
Study NCT00420147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wedged inshoe orthosis
Description: Treatment subjects were prescribed an inshoe wedged orthosis
Study NCT00420147 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: neutral inshoe orthosis
Description: Control subjects were prescribed a neutral inshoe orthosis
Study NCT00957996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: 300 mg twice daily
Study NCT00957996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: 600 mg once daily
Study NCT00066378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Study NCT00066378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Study NCT00066378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study NCT05584813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypobaric Hypoxia
Description: The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
Study NCT02809807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of the work of breathing
Description: We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
Study NCT02809807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gas Mask
Description: Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
Study NCT02414802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis will be used in both arms
Study NCT02414802 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: low-molecular-weight heparin calcium
Description: anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
Study NCT02414802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-molecular-weight heparin calcium
Description: anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
Study NCT02414802 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: urokinase
Description: A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
Study NCT03864341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to homelessness prevention services
Description: Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
Study NCT03864341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance use services
Description: Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
Study NCT03864341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Follow-up to assist participants in receiving homelessness prevention services
Study NCT03353142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equal Breathing
Description: * Blood pressure recorded at baseline, immediately pre- and post-trial~* Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~* PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~* TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry
Study NCT02414802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urokinase
Description: A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
Study NCT03305809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally.
Study NCT03305809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT01742845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided administration of ropivacaine 4.75 mg/ml
Study NCT01742845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: landmark based superfical ropivacaine 4.75 mg/ml injection
Study NCT03469492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
Study NCT03469492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Exercise in accordance to the guidelines established by the American Diabetes Association.
Study NCT03469492 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Dietary counseling in accordance to the guidelines established by the American Diabetes Association.